Selective Tumor Uptake of Boronophenylalanine-Fructose (BPA-F) in an Animal Model of Hepatic Colorectal Metastases
In 1998 more than 150,000 Americans will be diagnosed with colorectal cancer, and over 60,000 will die from this tumor. At the time of diagnosis, 15–25% will have hepatic metastases, and another 20–30% will develop metastatic hepatic lesions subsequent to resection of the primary tumors. Treatment options for hepatic metastases include aggressive surgical resection, administration of regional chemotherapeutic agents, sys temic chemotherapy, radiotherapy, or other palliative and experimental procedures. Despite well-defined pharmacological benefits of selected chemotherapeutics, there is no convincing survival advantage for many of the above mentioned techniques.1,2,3,4 The median survival after diagnosis is typically 22–24 months, and has changed minimally over the past decade.
KeywordsHepatic Metastasis Boron Concentration Boron Neutron Capture Therapy Normal Liver Tissue Beth Israel Deaconess Medical
Unable to display preview. Download preview PDF.
- 5.T. Pinelli, S. Altieri, F. Fossati, and A. Zonta, Development of a method to use boron neutron capture therapy for diffused tumours of liver (Taormina Project), in: “Cancer Neutron Capture Therapy,” Y. Mishima ed., Plenum Press, New York, 1996, pp. 783–794.Google Scholar
- 6.J. Coderre, A. Chanana, D. Joel, E. Elowitz, P. Micca, M. Nawrocky, M. Chadha, J. Gebbers, M. Shady, N. Peress, and D. Slatkin, Biodistribution of Boronophenylalanine in Patinets with Glioblastoma Multiforme: Boron Concentration Correlates with Tumor Cellularity, Rad. Res., 149:163–170, 1998.CrossRefGoogle Scholar